Curriculum Vitae

Personal information

Ilona Bruinsma

Work experience

CBG - MEB (NL) - Assessor Quality Biopharmaceuticals January 2024 - present

Main activity: Assessment of the quality of biopharmaceuticals

STARoDub BV (NL) – Sr. Regulatory Affairs Manager January 2021 – December 2023

Main activities
- Biotech products: writing/reviewing CMC sections for phase 1-3 IND/IMPD and MAA/BLA submission (pre-marketing; (RNA) vaccines)
- Biotech products: supporting in drafting of briefing books for scientific advise meetings
- Biotech products: coordinating and writing responses to questions from health authorities worldwide (both clinical phase and commercial)

STARoDub BV (NL) – Regulatory Affairs Manager August 2015 – December 2020

Main activities:
- Biotech products: writing/reviewing CMC sections for MAA/BLA submission (pre-marketing; vaccines)
- Biotech products: writing responses to questions from health authorities worldwide
- Biotech products: handling analytical and manufacturing process post-approval changes for Biotech products worldwide (recombinant protein)
- Preclinical development: review preclinical development strategy to assess probability of approval, writing preclinical parts of regulatory documents
- Small molecules: handling post-approval site changes for analytical testing, batch release and secondary packaging

Radboud University Medical Centre (NL) – Postdoctoral Research Scientist November 2013 – July 2015

Main activity: Development of new (genetical) biomarkers for early stage Alzheimer, Parkinson and multiple sclerosis (MS).

Radboud University Medical Centre (NL) – Postdoctoral Research Scientist November 2010 – Oktober 2013

Main activity: Study microRNAs as potential biomarkers and novel therapeutic target in MS. Achievement: Best Scientific Paper 2011, Radboud Alzheimer Centre, Nijmegen.

Education and training

Radboud University Medical Centre, Nijmegen (NL), March 2006 – September 2011 Ph.D., Medical Sciences (focus neurobiology of disease)
Thesis: Amyloidogenic proteins in Alzheimer's and Parkinson's disease: interaction with chaperones and inflammation (Sep 21th, 2011)

Radboud University, Nijmegen (NL), September 2020 – June 2005 M.Sc., Sciences (focus on biochemistry)
Major internship: Studying the effects of vigabatrin and R-baclofen on the electroencephalograms and behaviour of WAG/Rij rats, an animal model of absence epilepsy. In addition, I also studied the effect of vigabatrin on the amino acids and neurotransmitters concentration.
Minor internship: Development and evaluation of a calcium-sensing receptor agonist and antogonist

Additional information

Publications

1. Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. NPJ Parkinsons Dis. · Nov 30, 2021

2. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls. Molecular Neurobiology · Jul 1, 2019

3. Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. Journal of Neuroinflammation · Dec 1, 2017

4. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy. Molecular neurobiology · Dec 1, 2017

5. MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid.MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid. Molecular Neurbiology · Apr 21, 2015

6. Inhibition of α-synuclein aggregation by small heat shock proteins. Proteins: · Sep 1, 2011

7. Small heat shock proteins induce a cerebral inflammatory reaction. The Journal of Neuroscience · Aug 17, 2011

8. A rational design to create hybrid beta-sheet breaker peptides to inhibit aggregation and toxicity of amyloid-β. Medicinal Chemistry Communications, 2, 60-64 · Jan 1, 2011

9. Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated Abeta40 (DAbeta(1-40)) are modulated by sulfate moieties of heparin. Neuroscience Research · Apr 1, 2010

10. Apolipoprotein E protects cultured pericytes and astrocytes from D-Abeta(1-40)-mediated cell death. Brain Research · Feb 22, 2010

11. Sulfation of heparan sulfate associated with amyloid-beta plaques in patients with Alzheimer's disease. Acta Neuropathologica · Feb 1, 2010

Projects

Memberships

Other Relevant Information